Anthem Blue Cross Blue Shield of Colorado prior authorization, page 43

CPT code lookup

Each row is one code from the public prior authorization list. The description is the procedure or service name on that source row. This is not a coverage decision.

Prior authorization codes

Prior authorization codes
CodeDescriptionSource
81339MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10Colorado Prior Authorization List, Pg 102 Original policy
81340Trb@ (T Cell Antigen Receptor, Beta) (Eg, Leukemia And Lymphoma), Gene Rearrangement Analysis To Detect Abnormal Clonal Population(S); Using Amplification Methodology (Eg, PolColorado Prior Authorization List, Pg 102 Original policy
81341Trb@ (T Cell Antigen Receptor, Beta) (Eg, Leukemia And Lymphoma), Gene Rearrangement Analysis To Detect Abnormal Clonal Population(S); Using Direct Probe Methodology (Eg, SoutColorado Prior Authorization List, Pg 102 Original policy
81342Trg@ (T Cell Antigen Receptor, Gamma) (Eg, Leukemia And Lymphoma), Gene Rearrangement Analysis, Evaluation To Detect Abnormal Clonal Population(S)Colorado Prior Authorization List, Pg 102 Original policy
81343PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesColorado Prior Authorization List, Pg 102 Original policy
81344TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesColorado Prior Authorization List, Pg 102 Original policy
81345TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)Colorado Prior Authorization List, Pg 102 Original policy
81346TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)Colorado Prior Authorization List, Pg 102 Original policy
81347SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L)Colorado Prior Authorization List, Pg 102 Original policy
81348SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L)Colorado Prior Authorization List, Pg 102 Original policy
81349Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of- heterozygosity variants, low-passColorado Prior Authorization List, Pg 102 Original policy
81350UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, drug metabolism, hereditary unconjugated hyperbilirubinemia [Gilbert syndrome]) gene analysis, common varianColorado Prior Authorization List, Pg 102 Original policy
81351TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequenceColorado Prior Authorization List, Pg 102 Original policy
81352TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology)Colorado Prior Authorization List, Pg 103 Original policy
81353TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variantColorado Prior Authorization List, Pg 103 Original policy
81355Vkorc1 (Vitamin K Epoxide Reductase Complex, Subunit 1) (Eg, Warfarin Metabolism), Gene Analysis, Common Variants (Eg, -1639/3673)Colorado Prior Authorization List, Pg 103 Original policy
81357U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P)Colorado Prior Authorization List, Pg 103 Original policy
81360ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fsColorado Prior Authorization List, Pg 103 Original policy
81361HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); common variant(s) (eg, HbS, HbC, HbE)Colorado Prior Authorization List, Pg 103 Original policy
81362HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); known familial variant(s)Colorado Prior Authorization List, Pg 103 Original policy
81363HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); duplication/deletion variant(s)Colorado Prior Authorization List, Pg 103 Original policy
81364HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); full gene sequenceColorado Prior Authorization List, Pg 103 Original policy
81379Hla Class I Typing, High Resolution (Ie, Alleles Or Allele Groups); Complete (Ie, Hla-A, -B, And -C)Colorado Prior Authorization List, Pg 103 Original policy
81380Hla Class I Typing, High Resolution (Ie, Alleles Or Allele Groups); One Locus (Eg, Hla-A, -B, Or -C), EachColorado Prior Authorization List, Pg 103 Original policy
81381Hla Class I Typing, High Resolution (Ie, Alleles Or Allele Groups); One Allele Or Allele Group (Eg, B*57:01P), EachColorado Prior Authorization List, Pg 103 Original policy
81400MOLECULAR PATHOLOGY PROCEDURE LEVEL 1Colorado Prior Authorization List, Pg 103 Original policy
81401MOLECULAR PATHOLOGY PROCEDURE LEVEL 2Colorado Prior Authorization List, Pg 103 Original policy
81402MOLECULAR PATHOLOGY PROCEDURE LEVEL 3Colorado Prior Authorization List, Pg 103 Original policy
81403MOLECULAR PATHOLOGY PROCEDURE LEVEL 4Colorado Prior Authorization List, Pg 103 Original policy
81404MOLECULAR PATHOLOGY PROCEDURE LEVEL 5Colorado Prior Authorization List, Pg 103 Original policy
81405MOLECULAR PATHOLOGY PROCEDURE LEVEL 6Colorado Prior Authorization List, Pg 104 Original policy
81406MOLECULAR PATHOLOGY PROCEDURE LEVEL 7Colorado Prior Authorization List, Pg 104 Original policy
81407MOLECULAR PATHOLOGY PROCEDURE LEVEL 8Colorado Prior Authorization List, Pg 104 Original policy
81408Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, SColorado Prior Authorization List, Pg 104 Original policy
81410Aortic dysfunction or dilation (eg, Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); genomic sequence analysis panel, mustColorado Prior Authorization List, Pg 104 Original policy
81411Aortic dysfunction or dilation (eg, Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); duplication/deletion analysis panel, mColorado Prior Authorization List, Pg 104 Original policy
81412Ashkenazi Jewish associated disorders (eg, Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease)Colorado Prior Authorization List, Pg 104 Original policy
81413Cardiac ion channelopathies (eg Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panelColorado Prior Authorization List, Pg 104 Original policy
81414Cardiac ion channelopathies (eg Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); duplication/deletion gene analysColorado Prior Authorization List, Pg 104 Original policy
81415Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysisColorado Prior Authorization List, Pg 104 Original policy
81416Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) (List separately in addition to codeColorado Prior Authorization List, Pg 104 Original policy
81417Exome (eg, unexplained constitutional or heritable disorder or syndrome); re- evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/synColorado Prior Authorization List, Pg 104 Original policy
81418Drug metabolism (eg, pharmacogenomics) genomic sequence analysis panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplication/deletion anColorado Prior Authorization List, Pg 104 Original policy
81419Epilepsy genomic sequence analysis panel, must include analyses for ALDH7A1, CACNA1A, CDKL5, CHD2, GABRG2, GRIN2A, KCNQ2, MECP2, PCDH19, POLG, PRRT2, SCN1A, SCN1B, SCN2A, SCN8Colorado Prior Authorization List, Pg 104 Original policy
81425Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysisColorado Prior Authorization List, Pg 104 Original policy
81426Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (eg, parents, siblings) (List separately in addition to coColorado Prior Authorization List, Pg 104 Original policy
81427Genome (eg, unexplained constitutional or heritable disorder or syndrome); re- evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/sColorado Prior Authorization List, Pg 104 Original policy
81430Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); genomic sequence analysis panel, must include sequencing of at least 60 genes, including CDH23Colorado Prior Authorization List, Pg 104 Original policy
81431Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); duplication/deletion analysis panel, must include copy number analyses for STRC and DFNB1 deletColorado Prior Authorization List, Pg 105 Original policy
81432Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer, hereditary pancreatic cancer, hereditary prColorado Prior Authorization List, Pg 105 Original policy

Sources

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.